Findings

What do systematic reviews say?

127 questions · 132 findings · 13 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 13 · 9.8%GRADE not reported 4 · 3%Very low 31 · 23.5%Low 33 · 25%Moderate 27 · 20.5%High 24 · 18.2%

Pregabalin vs placebo

Ataxia · people with drug‐resistant focal epilepsy

Pregabalin may leads to higher adverse effect: ataxia compared with placebo (low certainty).

1 finding from 1 review

Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
RR 3.9 [2.05, 7.42]
6 studies · 1868 participants
Low

Pregabalin vs placebo

Dizziness · people with drug‐resistant focal epilepsy

Pregabalin may leads to higher adverse effect: dizziness compared with placebo (low certainty).

1 finding from 1 review

Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
RR 3.15 [2.23, 4.44]
7 studies · 2193 participants
Low

Pregabalin vs placebo

Adverse effect: fatigue · people with drug‐resistant focal epilepsy

Pregabalin showed no clear difference in adverse effect: fatigue compared with placebo (low certainty).

1 finding from 1 review

Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
RR 1.35 [0.94, 1.93]
8 studies · 2448 participants
Low

Pregabalin vs placebo

QoL · patients with chronic pancreatitis and pancreatic pain

1 finding from 1 review

Pregabalin for decreasing pancreatic pain in chronic pancreatitis 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 64 participants
Moderate

Pregabalin vs placebo

Serious adverse events · patients with chronic pancreatitis and pancreatic pain

Pregabalin showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Pregabalin for decreasing pancreatic pain in chronic pancreatitis 2016 · Cochrane Headline outcomes only
RR 1.76 [0.35, 8.96]
1 study · 64 participants
Low

Pregabalin vs placebo

Opiate analgesic requirement (short‐term) · patients with chronic pancreatitis and pancreatic pain

1 finding from 1 review

Pregabalin for decreasing pancreatic pain in chronic pancreatitis 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 64 participants
Moderate

Pregabalin vs placebo

Adverse events · patients with chronic pancreatitis and pancreatic pain

Pregabalin probably leads to higher adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Pregabalin for decreasing pancreatic pain in chronic pancreatitis 2016 · Cochrane Headline outcomes only
RR 1.71 [1.2, 2.43]
1 study · 64 participants
Moderate

Pregabalin vs placebo

Pain scores (short‐term) · patients with chronic pancreatitis and pancreatic pain

1 finding from 1 review

Pregabalin for decreasing pancreatic pain in chronic pancreatitis 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 64 participants
Moderate

Pregabalin vs placebo

Hospital admissions · patients with chronic pancreatitis and pancreatic pain

Pregabalin showed no clear difference in hospital admissions compared with placebo (low certainty).

1 finding from 1 review

Pregabalin for decreasing pancreatic pain in chronic pancreatitis 2016 · Cochrane Headline outcomes only
RR 0.44 [0.04, 4.62]
1 study · 64 participants
Low

Pregabalin vs placebo

At least 50% reduction in pain · adults with fibromyalgia

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1874 participants
High

Pregabalin vs placebo

Adverse events as N of participants with at least one adverse event objective · adults with fibromyalgia enrolled in EERW studies

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 687 participants
High

Pregabalin vs placebo

Serious adverse events · adults with fibromyalgia enrolled in EERW studies

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 687 participants
Very low

Pregabalin vs placebo

Death · adults with fibromyalgia enrolled in EERW studies

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 687 participants
Very low

Pregabalin vs placebo

PGIC very much improved · adults with fibromyalgia

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1869 participants
High

Pregabalin vs placebo

At least 30% reduction in pain · adults with fibromyalgia

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1874 participants
High

Pregabalin vs placebo

Moderate benefit · adults with fibromyalgia

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1869 participants
High

Pregabalin vs placebo

Lack of efficacy withdrawal · adults with fibromyalgia

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1874 participants
High

Pregabalin vs placebo

Withdrawals due to adverse events · adults with fibromyalgia

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1874 participants
High

Pregabalin vs placebo

Serious adverse events · adults with fibromyalgia

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1238 participants
Very low

Pregabalin vs placebo

Death · adults with fibromyalgia

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 3460 participants
Very low